BMY vs. SNY: Bristol-Myers Squibb vs. Sanofi Stock Comparison

November 11, 2026

How do Bristol-Myers Squibb (BMY) and Sanofi (SNY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Bristol-Myers Squibb (BMY) and Sanofi (SNY) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.

Bristol-Myers Squibb (BMY) trades as ordinary local shares, while Sanofi (SNY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for Bristol-Myers Squibb (BMY) and Sanofi (SNY)
Profile Item	BMY	SNY
Name	Bristol-Myers Squibb Company	Sanofi ADR
Country/Region	United States	France
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Pharmaceuticals	Pharmaceuticals
GICS Sub-Industry	Pharmaceuticals	Pharmaceuticals
Market Capitalization	127.02 billion USD	112.71 billion USD
Currency	USD	USD
Exchange	NYSE	Nasdaq
Listing Date	June 1, 1972	July 1, 2002
Security Type	Common Stock	ADR

Price Performance

Cumulative Growth

BMY

SNY

GSPC

Bristol-Myers Squibb (BMY) vs. Sanofi (SNY), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Bristol-Myers Squibb (BMY) and Sanofi (SNY). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Bristol-Myers Squibb (BMY) and Sanofi (SNY). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Bristol-Myers Squibb (BMY) and Sanofi (SNY)
Metric	BMY	SNY
Total Return (1Y)	38.62%	2.73%
Total Return (3Y, Annualized)	12.29%	6.89%
Total Return (5Y, Annualized)	5.09%	3.16%

Risk Profile

Drawdown History

BMY

SNY

GSPC

Bristol-Myers Squibb (BMY) vs. Sanofi (SNY), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Bristol-Myers Squibb (BMY) and Sanofi (SNY). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Bristol-Myers Squibb (BMY) and Sanofi (SNY)
Metric	BMY	SNY
Volatility (1Y, Annualized)	28.01%	23.60%
Beta (5Y)	0.19	0.28
Max Drawdown (5Y)	-47.67%	-33.52%
Avg. Volume (3M)	10.85M	3.29M

Risk-Adjusted Performance

Risk-Return Positioning

BMY and SNY are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Bristol-Myers Squibb (BMY) and Sanofi (SNY)
Metric	BMY	SNY
Sharpe Ratio (1Y)	1.23	-0.07
Sortino Ratio (1Y)	1.95	-0.10

Profitability

ROE (TTM)

Bristol-Myers Squibb (BMY) at 44.01% sits in the top ROE quartile, while Sanofi (SNY) at 5.72% is closer to the peer norm — stronger capital efficiency for BMY.

BMY

Pharmaceuticals, Biotechnology & Life Sciences industry group

44.01%

Max: 109.18%
BMY: 44.01%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.72%

Max: 109.18%
Q3: 6.23%
SNY: 5.72%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Bristol-Myers Squibb (BMY) vs. Sanofi (SNY): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Bristol-Myers Squibb (BMY) at 18.47% keeps the most of each sales dollar — above its industry’s net margin range — and Sanofi (SNY) at 8.20% also retains a top-quartile share.

BMY

Pharmaceuticals, Biotechnology & Life Sciences industry group

18.47%

BMY: 18.47%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.20%

Max: 18.05%
SNY: 8.20%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Bristol-Myers Squibb (BMY) vs. Sanofi (SNY): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Bristol-Myers Squibb (BMY) at 33.79% and Sanofi (SNY) at 30.89% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

BMY

Pharmaceuticals, Biotechnology & Life Sciences industry group

33.79%

Max: 83.12%
BMY: 33.79%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

30.89%

Max: 83.12%
SNY: 30.89%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Bristol-Myers Squibb (BMY) vs. Sanofi (SNY): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Bristol-Myers Squibb (BMY) and Sanofi (SNY)
Metric	BMY	SNY
ROE (TTM)	44.01%	5.72%
ROA (TTM)	10.90%	5.31%
Net Margin (TTM)	18.47%	8.20%
Operating Margin (TTM)	33.79%	30.89%
Gross Margin (TTM)	70.50%	73.68%

Growth

Revenue Growth

Both Bristol-Myers Squibb (BMY) at -0.22% and Sanofi (SNY) at 5.49% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Bristol-Myers Squibb (BMY) vs. Sanofi (SNY): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Sanofi (SNY) reports EPS growth of 39.43%, ranked against its industry; Bristol-Myers Squibb (BMY) has no EPS growth figure this period.

Bristol-Myers Squibb (BMY) vs. Sanofi (SNY): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Bristol-Myers Squibb (BMY) and Sanofi (SNY)
Metric	BMY	SNY
Revenue Growth (YoY)	-0.22%	5.49%
Revenue Growth (3Y CAGR)	1.45%	4.82%
EPS Growth (YoY)	--	39.43%
EPS Growth (3Y CAGR)	5.46%	6.02%

Financial Strength

Current Ratio (MRQ)

Both Bristol-Myers Squibb (BMY) at 1.59 and Sanofi (SNY) at 1.12 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

BMY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.59

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
BMY: 1.59
Min: 0.10

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.12

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
SNY: 1.12
Min: 0.10

Bristol-Myers Squibb (BMY) vs. Sanofi (SNY): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Sanofi (SNY) at 0.27 is near its industry mid-range for debt-to-equity ratio, while Bristol-Myers Squibb (BMY) at 1.91 sits above its benchmark range, pointing to a heavier debt load relative to equity.

BMY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.91

BMY: 1.91
Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.27

Max: 1.42
Q3: 0.65
SNY: 0.27
Median: 0.15
Q1: 0.02
Min: 0.00

Bristol-Myers Squibb (BMY) vs. Sanofi (SNY): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Bristol-Myers Squibb (BMY) and Sanofi (SNY)
Metric	BMY	SNY
Current Ratio (MRQ)	1.59	1.12
Debt / Equity (MRQ)	1.91	0.27
Net Debt / EBITDA	1.77	0.96

Dividends

Dividend Yield (TTM)

Sanofi (SNY) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bristol-Myers Squibb (BMY) reports a yield of 3.99%, ranking against industry peers normally.

BMY

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.99%

BMY: 3.99%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

SNY: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Bristol-Myers Squibb (BMY) vs. Sanofi (SNY): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Sanofi (SNY) reports payout ratio above 100% at 119.86%, meaning dividends exceeded current-period earnings and sustainability needs extra context. Meanwhile Bristol-Myers Squibb (BMY) reports 55.88%, ranking against industry peers normally.

BMY

Pharmaceuticals, Biotechnology & Life Sciences industry group

55.88%

BMY: 55.88%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

119.86%

SNY: 119.86%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Bristol-Myers Squibb (BMY) vs. Sanofi (SNY): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Bristol-Myers Squibb (BMY) and Sanofi (SNY)
Metric	BMY	SNY
Dividend Yield (TTM)	3.99%	0.00%
Dividend Payout Ratio (TTM)	55.88%	119.86%

Valuation

P/E Ratio (TTM)

Both Bristol-Myers Squibb (BMY) at 13.78 and Sanofi (SNY) at 23.40 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

BMY

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.78

Max: 85.34
Q3: 43.46
Median: 26.69
BMY: 13.78
Q1: 13.30
Min: 0.07

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.40

Max: 85.34
Q3: 43.46
Median: 26.69
SNY: 23.40
Q1: 13.30
Min: 0.07

Bristol-Myers Squibb (BMY) vs. Sanofi (SNY): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

Both Bristol-Myers Squibb (BMY) at 2.54 and Sanofi (SNY) at 2.21 fetch a relatively low price per dollar of sales, landing in the cheaper P/S ratio quartile of their industries.

BMY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.54

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
BMY: 2.54
Min: 0.01

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.21

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
SNY: 2.21
Min: 0.01

Bristol-Myers Squibb (BMY) vs. Sanofi (SNY): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Sanofi (SNY) at 1.38 sits in the lower P/B ratio quartile against book while Bristol-Myers Squibb (BMY) at 5.43 is valued near its industry’s middle — SNY is cheaper on assets, though weigh it against ROE and asset quality.

BMY

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.43

Max: 13.53
Q3: 6.54
BMY: 5.43
Median: 3.25
Q1: 1.69
Min: -5.59

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.38

Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
SNY: 1.38
Min: -5.59

Bristol-Myers Squibb (BMY) vs. Sanofi (SNY): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Bristol-Myers Squibb (BMY) and Sanofi (SNY)
Metric	BMY	SNY
P/E Ratio (TTM)	13.78	23.40
P/S Ratio (TTM)	2.54	2.21
P/B Ratio (MRQ)	5.43	1.38
Free Cash Flow Yield (TTM)	5.01%	7.17%